Company profile for Vaxil Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucintm and is also developing a tuberculosis vaccine / treatment that has demonstrated promising pr...
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucintm and is also developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
3 Pinhas Sapir Street, 3rd Floor, “Weizmann Science Park, 74140, Rehovot
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/04/3199629/0/en/Vaxil-Announces-Close-of-Previously-Announced-Non-Brokered-Private-Placement-and-Update-on-Board-of-Directors.html

GLOBENEWSWIRE
04 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193354/0/en/Vaxil-Announces-Update-on-Non-Brokered-Private-Placement.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176940/0/en/Vaxil-Announces-Non-Brokered-Private-Placement.html

GLOBENEWSWIRE
29 Oct 2025
Vaxil : Share Cosolidation
Vaxil : Share Cosolidation

06 May 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/05/06/3074939/0/en/VAXIL-SHARE-CONSOLIDATION.html

GLOBENEWSWIRE
06 May 2025
Vaxil: Management and Operational Update
Vaxil: Management and Operational Update

03 Apr 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/04/03/3055585/0/en/Vaxil-Management-and-Operational-Update.html

GLOBENEWSWIRE
03 Apr 2025

https://www.globenewswire.com/news-release/2025/03/31/3052800/0/en/VAXIL-s-Annual-and-Special-Shareholders-Meeting.html

GLOBENEWSWIRE
31 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty